Thymulin and peroxiredoxin 6 have protective effects against streptozotocin-induced type 1 diabetes in mice

Autor: Vladimir I. Novoselov, S. B. Parfenyuk, Mars G. Sharapov, Olga V. Glushkova, Sergey M Lunin, A. E. Gordeeva, Maxim O. Khrenov, T. V. Novoselova, Elena G Novoselova, E. E. Fesenko
Rok vydání: 2021
Předmět:
0301 basic medicine
Thymic Factor
Circulating
MAP Kinase Kinase 4
Anti-Inflammatory Agents
Antioxidants
chemistry.chemical_compound
Mice
0302 clinical medicine
Blood plasma
Drug Discovery
Immunology and Allergy
Original Research Article
NF-kappa B
signaling
streptozotocin-induced diabetes
medicine.drug
Signal Transduction
medicine.medical_specialty
Immunology
030209 endocrinology & metabolism
Diabetes Mellitus
Experimental
03 medical and health sciences
Thymulin
Interferon-gamma
Immune system
Diabetes mellitus
Internal medicine
medicine
Diabetes Mellitus
Animals
peroxiredoxin 6
Pharmacology
Type 1 diabetes
business.industry
SARS-CoV-2
Tumor Necrosis Factor-alpha
Interleukins
COVID-19
medicine.disease
Streptozotocin
NFKB1
cytokines
COVID-19 Drug Treatment
030104 developmental biology
Endocrinology
chemistry
Cytokine storm
business
Peroxiredoxin VI
thymulin
Zdroj: International Journal of Immunopathology and Pharmacology
ISSN: 2058-7384
Popis: Protective effects of peroxiredoxin 6 (PRDX6) in RIN-m5F β-cells and of thymulin in mice with alloxan-induced diabetes were recently reported. The present work was aimed at studying the efficiency of thymulin and PRDX6 in a type 1 diabetes mellitus model induced by streptozotocin in mice. Effects of prolonged treatment with PRDX6 or thymic peptide thymulin on diabetes development were evaluated. We assessed the effects of the drugs on the physiological status of diabetic mice by measuring blood glucose, body weight, and cell counts in several organs, as well as effects of thymulin and PRDX6 on the immune status of diabetic mice measuring concentrations of pro-inflammatory cytokines in blood plasma (TNF-α, interleukin-5 and 17, and interferon-γ), activity of NF-κB and JNK pathways, and Hsp90α expression in immune cells. Both thymulin and PRDX6 reduced the physiological impairments in diabetic mice at various levels. Thymulin and PRDX6 provide beneficial effects in the model of diabetes via very different mechanisms. Taken together, the results of our study indicated that the thymic peptide and the antioxidant enzyme have anti-inflammatory functions. As increasing evidences show diabetes mellitus as a distinct comorbidity leading to acute respiratory distress syndrome and increased mortality in patients with COVID-19 having cytokine storm, thymulin, and PRDX6 might serve as a supporting anti-inflammatory treatment in the therapy of COVID 19 in diabetic patients.
Databáze: OpenAIRE
Externí odkaz: